scout
News|Videos|November 3, 2023

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME